ADVA and PSNC showcase 1200G channel transmission at SC19
19.11.2019 17:45:00 EET | Business Wire | Press release
ADVA (FSE: ADV) today announced that it’s hosting a joint showcase with PSNC at SC19 that features the industry’s first 1200Gbit/s optical channel transmission. Built upon the ADVA FSP 3000 TeraFlex™ terminal, the demo underscores the power of adaptive technology to maximize bandwidth efficiency in any network scenario. Using fractional QAM capabilities to boost fiber utilization and channel capacity, the demo highlights how network operators and enterprises can cost-effectively inject capacity into their networks without major upgrades. At SC19, TeraFlex™ will carry 1200Gbit/s channels in a 150GHz window or 800Gbit/s channels in a 100GHz window, delivering an industry-leading spectral efficiency of 8bit/s/Hz. These figures set a new benchmark for a commercially available product. The ADVA FSP 3000 TeraFlex™ has now been shipping for several months.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20191119005670/en/
The FSP 3000 TeraFlex™ helps customers inject capacity into their networks without major upgrades (Photo: Business Wire)
“As we approach the Shannon Limit, our compact and open FSP 3000 TeraFlex™ provides an entirely new route to network capacity expansion. This demo reveals how operators can enhance optical paths and reduce cost per bit right now,” said Christoph Glingener, CTO, ADVA. “Transmission terminal design is all about utilizing fiber in the most efficient way, and that’s why our FSP 3000 TeraFlex™ is the high-speed terminal of choice. By providing a 1200Gbit/s channel that consumes only 150GHz of spectrum, we’re leading the industry with spectral efficiency and channel capacity. Compared with the promise of rival 800Gbit/s solutions that are still many months away, we’re delivering 50% more capacity today – and with the added bonus of significantly better reach.”
Presented at SC19, the live demo highlights how spectral efficiency is key to maximizing bandwidth in existing networks. It shows how super-channels in increments of 50GHz are ideal for maximizing client port flexibility while ensuring compatibility with legacy line systems. Using software-defined fractional QAM modulation and adaptive baud rate capabilities, the ADVA FSP 3000 TeraFlex™ can support 1200Gbit/s channels carrying three 400Gbit/s clients or 800Gbit/s channels carrying two 400Gbit/s clients. The reach and spectral efficiency of the dual-core coherent engine implementation is superior to future single-core 800Gbit/s concepts that have reduced client port flexibility and often leave spectrum unutilized.
“Terabit channels are fast becoming essential. Our network enables Europe’s scientific community to share huge data sets and access the most advanced supercomputing applications. But empowering those researchers to stay at the forefront of discovery requires a new level of reach and spectral efficiency. With this demo, we’re showing how mission-critical long-haul networks like ours, which are not fiber-rich, can meet unprecedented data demand,” commented Artur Binczewski, director, Network Division, PSNC. “The ADVA FSP 3000 TeraFlex™ provides the flexibility and granularity needed to squeeze maximum value from our fiber plant. Now we can transmit twelve 100Gbit/s or three 400Gbit/s signals in a single Terabit channel that consumes just 150GHz of spectrum. That level of efficiency enables us to achieve more than we ever thought possible with our DCI network.”
The demo will be on display at SC19 at booth 1955 until Thursday, November 21.
Further details of the demo are available in these slides: https://adva.li/sc19-slides.
About ADVA
ADVA is a company founded on innovation and focused on helping our customers succeed. Our technology forms the building blocks of a shared digital future and empowers networks across the globe. We’re continually developing breakthrough hardware and software that leads the networking industry and creates new business opportunities. It’s these open connectivity solutions that enable our customers to deliver the cloud and mobile services that are vital to today’s society and for imagining new tomorrows. Together, we're building a truly connected and sustainable future. For more information on how we can help you, please visit us at www.adva.com.
About PSNC
Poznan Supercomputing and Networking Center (PSNC) affiliated to the Institute of Bioorganic Chemistry of the Polish Academy of Sciences is an internationally known node of the European Research Area in the field of IT infrastructure of science and an important R&D center in the field of information and communication technologies (ICT). As a development center of e-Infrastructure, PSNC designed and built the Metropolitan Network POZMAN, High Performance Computing Center and the national broadband network PIONIER, maintained and still developed by PSNC. We are an institution of high development potential. A positive consequence of the Centre's exemplary activity in acquiring and implementing projects was the establishment of broad cooperation with international institutions. Projects developed at PSNC include cooperation with 927 units from 59 countries. All projects are focused on IT technology and concern new generation networks, grids, portals, digital libraries, IT energy efficiency, climate, weather, air quality, new sources of energy, digital humanities, personalized medicine, intelligent agriculture, industry 4.0, astronomy, bioinformatics, Big Data analysis, artificial intelligence, New Media, education, Smart City, cyber security. The list of areas of activity in which PSNC undertakes work is constantly expanding, providing an important example of taking up new technological challenges. www.man.poznan.pl/online/en
Published by:
ADVA Optical Networking SE, Munich, Germany
www.adva.com
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20191119005670/en/
Contact information
For press:
Gareth Spence
t +44 1904 699 358
public-relations@adva.com
For investors:
Stephan Rettenberger
t +49 89 890 665 854
investor-relations@adva.com
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
euNetworks launches new quantum-safe private connectivity service powered by Adtran’s encrypted optical transport technology27.5.2026 11:00:00 EEST | Press release
Adtran and euNetworks today announced their collaboration on the launch of a new quantum-safe private connectivity service, Quantum Shield. euNetworks has developed Quantum Shield using Adtran’s optical transport technology to augment its broader architecture, which is designed to deliver secure, scalable data center connectivity across euNetworks’ pan-European network. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260526610601/en/ Adtran’s encrypted optical transport technology is helping euNetworks deliver the highest levels of protection for sensitive data moving across Europe. The new offering is built for enterprises with stringent security, performance and customer-controlled encryption requirements. The deployment combines high-capacity dedicated infrastructure with real-time fiber monitoring and enhanced optical-layer visibility to safeguard critical traffic. By integrating advanced encryption with continuous monito
National Bank of Greece in Cyprus Goes Live With Smartstream’s Air to Consolidate Reconciliations27.5.2026 10:55:00 EEST | Press release
Smartstream, the trusted data solutions provider for leading global financial institutions and enterprises, today announces that the National Bank of Greece (NBG) in Cyprus has successfully gone live with Air, the company’s AI-enabled reconciliation solution. The go-live marks a significant step forward in the bank’s operational efficiency, reducing daily manual processing effort and eliminating the complexity of working across multiple data formats. The bank has deployed Air’s Cash module, replacing both incumbent and consolidating four separate reconciliation systems for Instant, Cash, SEPA, and Nostro reconciliations, into a single, intelligent platform. Although transaction volumes were manageable, the fragmented landscape required significant daily manual effort to handle items individually across each system and to navigate multiple data formats. Following a market review, the bank committed to Smartstream’s Air, with self service model and AI-enabled automation being a distinct
Duco Launches the First Agentic Operations Platform for Financial Services27.5.2026 10:20:00 EEST | Press release
Duco, today launched the first agentic Operations platform for financial services. Built on the engine that already processes 20 billion transactions every month for more than 200 clients, including seven of the top 20 banks and ten of the top 20 asset managers, the platform brings together everything firms need to run post-trade Operations alongside autonomous agents, safely and at scale. The launch establishes a breakthrough the industry has been waiting for. A tool surface, purpose-built for agents. Duco has unbundled its platform into a new alternative agent layer that reconfigures its platform into hundreds of discrete capabilities servicing post trade. Model Context Protocol (MCP) gives capabilities covering reconciliation, data preparation, data access, audit trails, exception management, document creation and more. For the first time, agents have a verified, deterministic toolset built specifically for post-trade. Agents do not replace matching, rules or audit; they use them. P
Brenus Pharma Announces FDA Acceptance of IND Application for STC-1010 (BreAK-CRC001) in MSS Metastatic Colorectal Cancer (mCRC)27.5.2026 09:49:00 EEST | Press release
Brenus Pharma, a clinical stage biotechnology company developing novel in vivo immunotherapies for solid tumors, announced that the U.S. Food and Drug Administration (FDA) has accept the company's Investigational New Drug (IND) application for its first drug candidate, STC-1010, in microsatellite stable (MSS) metastatic colorectal cancer (mCRC). STC-1010 is designed to address a critical unmet need worldwide. Approximately 95% of mCRC patients have MSS tumors, which demonstrate minimal response to standard immunotherapies. The FDA validated Brenus Pharma's advanced regulatory and manufacturing capabilities. This operational readiness will accelerate patient access and data generation across both European and US sites for a Phase II program planned for 2027. "FDA's acceptance of our IND represents a major validation of our program and enables the full execution of our clinical strategy across Europe and the United States. Achieving regulatory alignment across multiple jurisdictions refl
Alfasigma presents first data on filgotinib from the Phase 3 OLINGUITO trial in axial spondyloarthritis at EULAR 202627.5.2026 09:00:00 EEST | Press release
Alfasigma S.p.A, a global pharmaceutical company with a focus on innovation in rare and specialty care where there is significant unmet patient need, presented positive results from the OLINGUITO Phase 3 clinical trial (NCT05785611iEudraCT 2022-501354-10-01ii) at EULAR 2026. In OLINGUITO filgotinib, an oral, once-daily JAK1 preferential inhibitor under investigation for the treatment of adult patients with active axial spondyloarthritis (axSpA), demonstrated sustained improvements in the signs and symptoms of axSpA, including disease activity and inflammation.iii Safety was consistent with the known profile of filgotinib, indicating a favourable benefit-risk profile for patients with active axSpA.iii The OLINGUITO trial consists of two international, randomised, double-blind, placebo-controlled studies (Study A and Study B), evaluating the efficacy and safety of filgotinib 200mg once-daily vs. placebo in patients with an established diagnosis of axSpA as per ASAS classification.i Eligi
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
